Gland Pharma Limited

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Schedule of meet

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about the transcript of the Analysts/Institutional Investor Meet/Con. Call Updates.

Gland Pharma Limited

Gland Pharma Limited has appointed Mr. Deepak Sapra as its Chief Executive Officer, effective November 16, 2026.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Copy of Newspaper Publication. The company has published unaudited financial results for the quarter ended June 30, 2026, which are available on the company's website and on the websites of the Stock Exchanges.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about the link of recording of the Analysts/Institutional Investor Meet/Con. Call Updates.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about the schedule of meet with analysts/institutional investors.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Investor Presentation. The presentation provides general background information about the company's activities as at the date of the presentation. The company has cautioned that the information contained in the presentation may not be relied upon for making any investment decisions and that the forward-looking statements may be subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the presentation.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding a press release dated August 10, 2026, titled 'Press Release on Q1FY27 Financial Results'. The press release contains the company's Q1FY27 financial results, which include revenue and profit details. The company's management has expressed optimism about the results, and the release also includes information about the company's growth prospects and future plans.

Gland Pharma Limited

Gland Pharma Limited has submitted its financial results for the period ended June 30, 2026, to the Exchange. The Board Meeting was held on August 11, 2022, and the financial results were prepared in accordance with Indian Accounting Standards. The company's financial results were reviewed and recommended by the Audit Committee. The Board Meeting concluded at 11:55 AM and ended at 11:55 PM.

Gland Pharma Limited

Gland Pharma Limited has announced a strategic CDMO partnership with a global pharmaceutical company, expanding its manufacturing capabilities and product offerings.

Gland Pharma Limited

Gland Pharma Limited has entered into a strategic, technical, manufacturing, or marketing tie-up with a global partner, Global Pharma, to provide sterile injectable products across various stages of development, including commercial, pipeline, and in-licensed products.

Gland Pharma Limited

Gland Pharma Limited has entered into a strategic collaboration with Neuland Laboratories for sterile API manufacturing. The partnership will enable Gland Pharma to expand its sterile API manufacturing capacity and serve growing demand for sterile products.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about a copy of newspaper publication regarding the 48th Annual General Meeting (AGM) notice, e-voting details, and dividend information.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding 'Letter to Shareholders regarding the dispatch of 48th AGM Notice and Annual report for the FY 2025-26'.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding 'BRSR Report for the year ended March 31, 2026'. The report also forms part of the Annual Report for the year 2025-26, submitted to the Stock Exchanges vide letter dated July 31, 2026, and can also be accessed on the company's website at http://glandpharma.com

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 25, 2026.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding the allotment of equity shares on exercise of ESOPs.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Options to purchase securities

Gland Pharma Limited

Gland Pharma Limited has received approval for Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials from the United States Food and Drug Administration (FDA). The company has successfully launched the product on the market, with sales of over $11 billion for the month of April 2026. Gland Pharma was established in 1978 and has grown over the years to become one of the largest pharmaceutical companies in India, with a global presence in over 60 countries.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Copy of Newspaper Publication. The company has published a copy of the newspaper publication in the newspapers Business Standard and Business Standard on 22nd August 2022. The publication includes the company's annual general meeting notice, the company's address, and the contact details of the company's representatives.